Pfizer's questionable press release timing and revenue update regarding COVID products.
-
The timing of the press release raised questions about burying bad news and lack of transparency. • 0:00
-
The opening of European markets for PAX loid was highlighted, providing greater access to the Coronavirus protease inhibitor. • 0:00
-
The press release was issued on a Friday at 4:30 p.m. during a global crisis, raising suspicions of evasiveness. • 0:00
-
Approximately 7.9 million treatment courses of government inventory were returned. • 0:00
-
Pfizer revised revenue guidance for 2023 due to COVID products, reducing PAX loid revenues by 7 billion. • 0:00
Important safety information about Pfizer vaccine, including risks for adolescents and pregnant individuals.
-
Pfizer’s revision of revenue estimates due to lower vaccination rates and non-cash reversals. • 4:45
-
Adolescent males 12-17 most affected by myocarditis post-vaccination. • 6:45
-
Subclinical myocarditis risks not adequately addressed in Pfizer’s release. • 7:29
-
Importance of informing vaccination provider about medical conditions, including allergies and fever. • 8:00
-
Concerns raised about using vaccine in pregnant individuals without risk differentiation. • 8:24
Pfizer discloses risks associated with its vaccine, highlighting concerns about long-term autoimmune complications.
-
FDA mandates disclosure of risks associated with Pfizer’s vaccine and other product. • 9:26
-
Concerns raised about potential long-term autoimmune complications due to immunestimulatio. • 11:15
-
Importance of understanding disease mechanisms and long-term impacts of vaccinatio. • 12:02
-
Research indicates likelihood of significant increase in autoimmunity over the next few year. • 12:10
-
Urgency in addressing concerns amidst an international crisi. • 12:55